Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2014

Open Access 01-12-2014 | Research article

Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients

Authors: Jong Sun Park, Hyo Jin Park, Young Sik Park, Sang-Min Lee, Jae-Joon Yim, Chul-Gyu Yoo, Sung Koo Han, Young Whan Kim

Published in: BMC Pulmonary Medicine | Issue 1/2014

Login to get access

Abstract

Background

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease of unknown causes. Three proteins (mammalian target of rapamycin, mTOR; zinc finger E-box-binding homeobox 1, ZEB1; Rho-associated, coiled-coil containing protein kinase 1, ROCK1) may be related to pulmonary fibrosis. However, they have not been assessed in human pulmonary fibrosis. We assessed the clinical significance of mTOR, ZEB1, and ROCK1 expression in human pulmonary fibrosis of usual interstitial pneumonia (UIP) pattern.

Methods

The mTOR, ZEB1, and ROCK1 expression was evaluated by immunohistochemical staining of 30 surgical lung biopsy tissues from 26 IPF and 4 UIP pattern connective tissue disease related interstitial lung disease (CTD-ILD) patients. The expression scores correlated with the clinical features.

Results

The mTOR, ZEB1 and ROCK1 mainly expressed in alveolar epithelial cells of UIP lungs. The histological fibrosis scores and lung function decline in the strong mTOR expression group were higher than those in the weak and intermediate expression group. Patients with positive ZEB1 expression had higher fibrosis scores and greater decline in carbon monoxide diffusion capacity (DLCO) than patients with negative ZEB1 expression. Patients with positive mTOR or ZEB1 expression had poorer prognosis than that of patients with negative mTOR or ZEB1 expression, although it was not statistically significant. ROCK1 was not associated with the studied clinicopathological features.

Conclusions

The mTOR and ZEB1 expression in pulmonary fibrosis patients significantly correlated with the fibrosis score and lung function decline, indicating that it may be related to the prognosis of pulmonary fibrosis. Further studies involving large numbers of homogeneous IPF patients are warranted.
Appendix
Available only for authorised users
Literature
1.
go back to reference King TE, Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet. 2011, 378 (9807): 1949-1961. 10.1016/S0140-6736(11)60052-4.CrossRefPubMed King TE, Pardo A, Selman M: Idiopathic pulmonary fibrosis. Lancet. 2011, 378 (9807): 1949-1961. 10.1016/S0140-6736(11)60052-4.CrossRefPubMed
2.
go back to reference Hartford CM, Ratain MJ: Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007, 82 (4): 381-388. 10.1038/sj.clpt.6100317.CrossRefPubMed Hartford CM, Ratain MJ: Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007, 82 (4): 381-388. 10.1038/sj.clpt.6100317.CrossRefPubMed
3.
go back to reference Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, Hardie WD: Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2009, 41 (5): 562-572. 10.1165/rcmb.2008-0377OC.CrossRefPubMedPubMedCentral Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, Hardie WD: Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2009, 41 (5): 562-572. 10.1165/rcmb.2008-0377OC.CrossRefPubMedPubMedCentral
4.
go back to reference Buschhausen L, Kamm M, Arns W, Schulze-Lohoff E, Weber M: [Successful treatment of a severe case of idiopathic pulmonary fibrosis with rapamycin]. Med Klin (Munich). 2005, 100 (3): 161-164. 10.1007/s00063-005-1015-3.CrossRef Buschhausen L, Kamm M, Arns W, Schulze-Lohoff E, Weber M: [Successful treatment of a severe case of idiopathic pulmonary fibrosis with rapamycin]. Med Klin (Munich). 2005, 100 (3): 161-164. 10.1007/s00063-005-1015-3.CrossRef
5.
go back to reference Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008, 10 (5): 593-601. 10.1038/ncb1722.CrossRefPubMed Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008, 10 (5): 593-601. 10.1038/ncb1722.CrossRefPubMed
6.
go back to reference Cho JH, Gelinas R, Wang K, Etheridge A, Piper MG, Batte K, Dakhallah D, Price J, Bornman D, Zhang S, March C, Galas D: Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes. BMC Med Genomics. 2011, 4: 8-10.1186/1755-8794-4-8.CrossRefPubMedPubMedCentral Cho JH, Gelinas R, Wang K, Etheridge A, Piper MG, Batte K, Dakhallah D, Price J, Bornman D, Zhang S, March C, Galas D: Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes. BMC Med Genomics. 2011, 4: 8-10.1186/1755-8794-4-8.CrossRefPubMedPubMedCentral
7.
go back to reference Shimizu Y, Dobashi K, Iizuka K, Horie T, Suzuki K, Tukagoshi H, Nakazawa T, Nakazato Y, Mori M: Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis. Am J Respir Crit Care Med. 2001, 163 (1): 210-217. 10.1164/ajrccm.163.1.2001089.CrossRefPubMed Shimizu Y, Dobashi K, Iizuka K, Horie T, Suzuki K, Tukagoshi H, Nakazawa T, Nakazato Y, Mori M: Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis. Am J Respir Crit Care Med. 2001, 163 (1): 210-217. 10.1164/ajrccm.163.1.2001089.CrossRefPubMed
8.
go back to reference American Thoracic Society/European Respiratory Society : American Thoracic Society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002, 165 (2): 277-304.CrossRef American Thoracic Society/European Respiratory Society : American Thoracic Society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002, 165 (2): 277-304.CrossRef
9.
go back to reference Park YS, Park CM, Lee HJ, Goo JM, Chung DH, Lee SM, Yim JJ, Kim YW, Han SK, Yoo CG: Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Respir Med. 2013, 107 (2): 256-262. 10.1016/j.rmed.2012.10.011.CrossRefPubMed Park YS, Park CM, Lee HJ, Goo JM, Chung DH, Lee SM, Yim JJ, Kim YW, Han SK, Yoo CG: Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Respir Med. 2013, 107 (2): 256-262. 10.1016/j.rmed.2012.10.011.CrossRefPubMed
10.
go back to reference Ashcroft T, Simpson JM, Timbrell V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988, 41 (4): 467-470. 10.1136/jcp.41.4.467.CrossRefPubMedPubMedCentral Ashcroft T, Simpson JM, Timbrell V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988, 41 (4): 467-470. 10.1136/jcp.41.4.467.CrossRefPubMedPubMedCentral
11.
go back to reference Akira M, Sakatani M, Ueda E: Idiopathic pulmonary fibrosis: progression of honeycombing at thin-section CT. Radiology. 1993, 189 (3): 687-691. 10.1148/radiology.189.3.8080483.CrossRefPubMed Akira M, Sakatani M, Ueda E: Idiopathic pulmonary fibrosis: progression of honeycombing at thin-section CT. Radiology. 1993, 189 (3): 687-691. 10.1148/radiology.189.3.8080483.CrossRefPubMed
12.
go back to reference Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005, 17 (6): 596-603. 10.1016/j.ceb.2005.09.009.CrossRefPubMed Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005, 17 (6): 596-603. 10.1016/j.ceb.2005.09.009.CrossRefPubMed
13.
go back to reference Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol. 2006, 17 (5): 1395-1404. 10.1681/ASN.2005050549.CrossRefPubMed Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol. 2006, 17 (5): 1395-1404. 10.1681/ASN.2005050549.CrossRefPubMed
14.
go back to reference Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int. 2006, 69 (11): 2029-2036. 10.1038/sj.ki.5000161.CrossRefPubMed Wu MJ, Wen MC, Chiu YT, Chiou YY, Shu KH, Tang MJ: Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int. 2006, 69 (11): 2029-2036. 10.1038/sj.ki.5000161.CrossRefPubMed
15.
go back to reference Kramer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H: Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol. 2008, 294 (2): F440-449.CrossRefPubMed Kramer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H: Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol. 2008, 294 (2): F440-449.CrossRefPubMed
16.
go back to reference Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F: Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2011, 55 (2): 388-398. 10.1016/j.jhep.2010.10.044.CrossRefPubMed Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F: Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2011, 55 (2): 388-398. 10.1016/j.jhep.2010.10.044.CrossRefPubMed
17.
go back to reference Mehrad B, Burdick MD, Strieter RM: Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol. 2009, 41 (8–9): 1708-1718.CrossRefPubMedPubMedCentral Mehrad B, Burdick MD, Strieter RM: Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol. 2009, 41 (8–9): 1708-1718.CrossRefPubMedPubMedCentral
18.
go back to reference Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, Chambers RC, Egan JJ: The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J. 2002, 19 (6): 1124-1127. 10.1183/09031936.02.00281602.CrossRefPubMed Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, Chambers RC, Egan JJ: The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J. 2002, 19 (6): 1124-1127. 10.1183/09031936.02.00281602.CrossRefPubMed
19.
go back to reference Fernandez IE, Eickelberg O: New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012, 380 (9842): 680-688. 10.1016/S0140-6736(12)61144-1.CrossRefPubMed Fernandez IE, Eickelberg O: New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012, 380 (9842): 680-688. 10.1016/S0140-6736(12)61144-1.CrossRefPubMed
20.
go back to reference Nair RV, Huang X, Shorthouse R, Adams B, Brazelton T, Braun-Dullaeus R, Morris RE: Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc. 1997, 29 (1–2): 614-615.CrossRefPubMed Nair RV, Huang X, Shorthouse R, Adams B, Brazelton T, Braun-Dullaeus R, Morris RE: Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc. 1997, 29 (1–2): 614-615.CrossRefPubMed
21.
go back to reference Gao Y, Xu X, Ding K, Liang Y, Jiang D, Dai H: Rapamycin inhibits transforming growth factor beta1-induced fibrogenesis in primary human lung fibroblasts. Yonsei Med J. 2013, 54 (2): 437-444. 10.3349/ymj.2013.54.2.437.CrossRefPubMedPubMedCentral Gao Y, Xu X, Ding K, Liang Y, Jiang D, Dai H: Rapamycin inhibits transforming growth factor beta1-induced fibrogenesis in primary human lung fibroblasts. Yonsei Med J. 2013, 54 (2): 437-444. 10.3349/ymj.2013.54.2.437.CrossRefPubMedPubMedCentral
23.
go back to reference ten Dijke P, Hill CS: New insights into TGF-beta-Smad signalling. Trends Biochem Sci. 2004, 29 (5): 265-273. 10.1016/j.tibs.2004.03.008.CrossRefPubMed ten Dijke P, Hill CS: New insights into TGF-beta-Smad signalling. Trends Biochem Sci. 2004, 29 (5): 265-273. 10.1016/j.tibs.2004.03.008.CrossRefPubMed
24.
go back to reference Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonne S, van Roy F, Mikulits W, Schreiber M, Brabletz T, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A: The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett. 2007, 581 (8): 1617-1624. 10.1016/j.febslet.2007.03.026.CrossRefPubMedPubMedCentral Aigner K, Descovich L, Mikula M, Sultan A, Dampier B, Bonne S, van Roy F, Mikulits W, Schreiber M, Brabletz T, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A: The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. FEBS Lett. 2007, 581 (8): 1617-1624. 10.1016/j.febslet.2007.03.026.CrossRefPubMedPubMedCentral
25.
go back to reference Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL: Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001, 12 (1): 27-36. 10.1091/mbc.12.1.27.CrossRefPubMedPubMedCentral Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL: Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001, 12 (1): 27-36. 10.1091/mbc.12.1.27.CrossRefPubMedPubMedCentral
26.
go back to reference Das S, Becker BN, Hoffmann FM, Mertz JE: Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol. 2009, 10: 94-10.1186/1471-2121-10-94.CrossRefPubMedPubMedCentral Das S, Becker BN, Hoffmann FM, Mertz JE: Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol. 2009, 10: 94-10.1186/1471-2121-10-94.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical significance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary fibrosis patients
Authors
Jong Sun Park
Hyo Jin Park
Young Sik Park
Sang-Min Lee
Jae-Joon Yim
Chul-Gyu Yoo
Sung Koo Han
Young Whan Kim
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2014
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-14-168

Other articles of this Issue 1/2014

BMC Pulmonary Medicine 1/2014 Go to the issue